Vitaccess

About Vitaccess

Vitaccess operates as a patient-centered research organization, specializing in generating real-world evidence (RWE) for the biopharmaceutical market. Founded in 2017 by Dr. Mark Larkin, who possesses nearly two decades of experience in healthcare consulting and finance, the company was established to merge digital technology with scientific research. Dr. Larkin, holding a PhD from the University of Cambridge, identified an opportunity to create a company that not only advises on RWE but also generates the primary data directly from patients and caregivers.

The company’s core offering is the Vitaccess Real™ platform, a proprietary, cloud-based system that collects data through smartphone apps. This platform enables the deployment of global, longitudinal studies to capture patient-reported outcomes (PROs), disease burden, treatment impact, and quality of life data in real-time. Vitaccess manages the entire study process, from protocol design and ethics submissions to participant recruitment and data analysis. Its business model involves providing these end-to-end research services to clients, primarily pharmaceutical companies, who use the generated evidence to support regulatory submissions to bodies like the FDA and EMA, inform health technology assessments, and guide product positioning.

Vitaccess serves a global clientele, with a strong focus on studies in rare diseases, oncology, and other chronic illnesses. A key aspect of its methodology is the co-creation of studies with patients, advocacy groups, and clinical experts to ensure the relevance and engagement of the research. The company bootstrapped to profitability and has received backing from Innovate UK and a grant from Tech Nation. Headquartered in Oxford, UK, with a presence in Switzerland, the company has established itself within the digital health landscape, winning awards such as the Queen's Award for Enterprise for Innovation.